Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
T-TherapeuticsUK - Cambridge
1 program1
Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
2028
2029
T-TherapeuticsIntracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
DebiopharmDebio 0123
Clinical Trials (2)
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
Start: Jun 2026Est. completion: Jul 2029
Phase 2Not Yet Recruiting
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Start: May 2023Est. completion: Sep 2028
Phase 1/2Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
14m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
14m ago
Office Administrator
SystImmune
15m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
25m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
29m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
29m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
2 companies competing in this space